Koselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed by surgery in children from 3 years of age with neurofibromatosis type 1 (NF1). NF1 is rare, and Koselugo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 31 July 2018. Further information on the [orphan designation](/en/medicines/human/orphan-designations/eu-3-18-2050) is available. Koselugo contains the active substance selumetinib.
Therapeutic Indication
### Therapeutic indication Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above
Therapeutic Area (MeSH)
ATC Code
N/A
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Koselugo
Medicine Name
Koselugo
Aliases
N/ANo risk management plan link.
